Experimental CAR-T therapy targets tough blood cancers in small early trial
Disease control
Completed
This early-phase study tested a new treatment called RD13-02, which uses a patient's own immune cells modified to attack cancer cells with a specific marker (CD7). It involved just 2 people with blood cancers like T-cell acute lymphoblastic leukemia that had come back or not resp…
Phase: EARLY_PHASE1 • Sponsor: MEI HENG • Aim: Disease control
Last updated May 04, 2026 16:24 UTC